NEU 723
Alternative Names: NEU-723Latest Information Update: 10 Nov 2023
At a glance
- Originator Neuron23; Origenis
- Developer Neuron23
- Class Anti-inflammatories; Antiparasitics; Antiparkinsonians; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
- Preclinical Inflammation
Most Recent Events
- 26 Oct 2023 Neuron23 terminates a phase-I trial in Parkinson's disease (In adults, In the elderly, In volunteers) in New Zealand (PO) due to business decision (NCT05633745)
- 30 Jan 2023 Phase-I clinical trials in Parkinson's disease (In adults, In the elderly, In volunteers) in New Zealand (PO) (NCT05633745)
- 19 Oct 2022 Preclinical trials in Inflammation in USA (unspecified route) (Neuron23 pipeline, October 2022)